Head-To-Head Review: Upstream Bio (NASDAQ:UPB) versus Neuphoria Therapeutics (NASDAQ:NEUP)

Upstream Bio (NASDAQ:UPB) and Neuphoria Therapeutics (NASDAQ:NEUP) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares Upstream Bio and Neuphoria Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Upstream Bio	N/A	N/A	N/A
Neuphoria Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Upstream Bio and Neuphoria Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1	2	4	0	2.43
Neuphoria Therapeutics	1	2	0	0	1.67

Upstream Bio currently has a consensus target price of $29.67, suggesting a potential upside of 963.32%. Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 106.49%. Given Upstream Bio’s stronger consensus rating and higher probable upside, research analysts clearly believe Upstream Bio is more favorable than Neuphoria Therapeutics.

Valuation & Earnings

This table compares Upstream Bio and Neuphoria Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	N/A	N/A	N/A	($2.90)	-0.96
Neuphoria Therapeutics	$1.17 million	15.62	-$33.66 million	($6.22)	-0.55

Upstream Bio has higher earnings, but lower revenue than Neuphoria Therapeutics. Upstream Bio is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Upstream Bio beats Neuphoria Therapeutics on 5 of the 7 factors compared between the two stocks.

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.